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Abstract
The decision in September 2011 in the UK to accept
blood donations from non-practicing men who have
sex with men (MSM) has received significant public
attention. Will this rule change substantially boost the
number of blood donations or will it make our blood
less safe? Clearly, most European countries have a
blood procurement problem. Fewer young people are
donating, while the population is aging and more
invasive therapies are requiring more blood. Yet if
that was the reason for allowing non-practicing MSM
to donate, clearly re-admission of some other, much
larger populations that are currently deferred from
donation should likewise be considered. As far as risks
for blood safety are concerned, evidence has been
provided that the current quality of infectious disease
marker testing significantly mitigates against, although
does not completely eradicate, risks associated with
admission of donors with a high risk of carrying
certain blood-transmissible agents. However, it could
be argued that more effective recruitment of the non-
donor pool, which is substantially larger than the
group of currently ineligible donors, would be a
better strategy. Recruitment of this group will benefit
the availability of blood without jeopardizing the
current excellent safety profile of blood.
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Background
Demand for blood is ever-increasing as continuous
improvements in medicine have ensured that people live
longer, and thus will cumulatively receive more (blood-
consuming) medical treatment. No adequate synthetic
or bio-engineered alternatives for blood, that is, no
pharmaceuticals which might replace lost oxygen carry-
ing capacity or primary hemostasis, have been
developed. In contrast to most other pharmaceuticals,
therefore, blood comes from a very poorly controlled
source: volunteer donors. Blood donors are exposed to
all kinds of environmental factors, which are, at least in
theory, transmissible with the donated blood, including
infectious agents and pharmaceuticals.
To ensure blood safety, a long list of anamnestic
exclusion criteria has accumulated [1]. This includes
individuals who have recently undergone medical inter-
ventions potentially associated with bacteremia or viral
infection, those who have travelled to places with
increased risk for certain infectious agents, people who
take certain medications, and also those whose behavior
predisposes them to a higher risk for blood-born infec-
tions, such as men who have sex with men (MSM). In
this way, scores of volunteers who would be willing to
donate blood are deferred, many of them indefinitely. In
an increasingly risk-averse society such as ours, new
exclusion criteria are defined, while existing ones are
rarely challenged. However, it is becoming difficult to
satisfy the increasing need for blood in an aging popula-
tion where the younger generation is notoriously hard
to motivate to donate blood.
In September 2011, one exclusion criterion was repealed
in the UK in response to pressure from special interest
groups. This decision caused quite a splash: “Men who
have sex with other men will be allowed to donate blood”
reads a BBC News headline [2]. Hailed or cursed as the lift
of the ban of MSM from blood donation in Britain by gay-
rights-advocates or opponents, the rule does nothing more
than relax donor eligibility rules to include MSM who
have abstained from homosexual intercourse for ≥ 12
months. This is far from the revolution it has been per-
ceived to be by the public on both sides of the fence. This
commentary will discuss if or how this change will affect
blood supply or (perceived) blood safety. Moreover, we
will briefly report on prospected blood use vs. blood avail-
ability, and provide a short paragraph on how currently
the infectious safety of blood is ascertained.
Blood donor eligibility
“Men who have sex with other men will be allowed to
donate blood” [2]. How big an issue is the change in
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many men engage, or have ever engaged, in sexual inter-
course with men are hard to ascertain. Consistently, a
frequency in excess of 5% of all men has been reported
[3]. With > 50% of all newly diagnosed cases of HIV
within their population, MSM indisputably remain the
most significant risk population [4].
That said, predicting how the change in donor eligibility
rules in Britain will affect blood donor behavior and blood
safety is not straight-forward. For starters, it is impossible
to estimate how many individuals are affected by the rule
change. We neither know how many abstinent MSM
there are nor how many of them aspire to becoming regu-
lar blood donors. At the same time, it is known that sexu-
ally active MSM were not necessarily deterred by the ban
on blood donation, but that some of them rather donated
quite regularly, to obtain free and anonymous HIV screen-
ing [5]. For the past decade, with few exceptions, all first-
time HIV serology or nucleic acid testing (NAT) positive
blood donors diagnosed at our institution admitted to
being MSM, having withheld their sexual orientation upon
previous donations (unpublished data). Even though
donors from risk populations are requested to suggest dis-
posal of their donor blood, with rare exceptions, those
men had not. Thus the blood of many infectious disease
marker (IDM)-negative MSM has been unwittingly trans-
fused; however, thanks to sensitive screening technology,
most of the potential harm was averted. With this in
mind, admission of non-practicing MSM, whose risk at
being in the window period of currently used diagnostic
tests should be the same as in the general population if
they flocked to the blood drives, might even increase
rather than decrease the safety of our blood supply, by
diluting the contribution of practicing (high-risk) MSM.
Realistically, however, dramatic quantitative or qualitative
consequences of the “British revolution” for the blood sup-
ply must not be expected [5].
How secure is our blood supply?
The two tasks of the transfusion medicine community -
optimal blood safety and a steady supply of blood - are
mutually exclusive if taken to the extreme. Clearly, mod-
ern medicine, in spite of blood-saving technologies,
requires more and more blood. A multitude of reasons
or this has been mentioned, the most important being
ever more aggressive, blood-consuming therapies and an
aging population whose prolonged biological youthful-
ness extends their eligibility for novel, highly invasive
treatments recently reviewed in [6]]. At the same time,
blood is becoming an increasingly scarce commodity:
The young population is shrinking, as is their willing-
ness to donate blood. Public support of the idea of
blood donation as a public service is dwindling, and the
federal government continues to tighten eligibility
criteria. A dramatic disparity of supply and demand of
blood products is imminent [6].
Activities, such as implementation of optimal blood
use programs, development of evidence-based indica-
tions for blood use and “optimized donation manage-
ment” can reduce blood consumption and waste and
thus slow the growth of blood use, and the recent
increase of maximum donor age has provided temporary
relief [7,8]. However, the question on how to meet
future demand, even if it did not increase, remains
unanswered.
After the recent act of allowing non-practicing MSM
to donate blood, we should pause to ask whether some
reasons for donor exclusion might not be comparatively
esoteric, and whether their lifting might actually have
some tangible benefit for the availability of blood with-
out entailing measurable recipient risks. Creutzfeld
Jacob’s disease New Variant (vCJD) may be a good
example. At the peak of the Bovine Spongiform Ence-
phalopathy (BSE) crisis 10 to 15 years ago, the cumula-
tive world-wide annual incidence of vCJD never
exceeded 30 individuals, for a combined total of slightly
more than 200 cases. Four patients developed vCJD sev-
eral years after receiving blood that had not been leuko-
cyte depleted from donors who had later succumbed to
vCJD. However, whether these cases were transfusion-
transmitted is by no means self-evident [9], and non-
leukocyte depleted blood is no longer used in most
countries. The indefinite deferral of donors who spent >
6 months in the UK during the BSE era has likely cost
us, and continues to cost us, millions of units of, most
likely, perfectly safe blood. Similarly, changes in eligibil-
ity for donors with a history of travel, surgical interven-
tions or taking medications could likewise be imagined
without risking adverse effects on transfusion safety.
Thus, certain current exclusion criteria can probably be
relaxed without sacrificing the (perceived) safety of
blood to which society has grown accustomed.
In addition to loss of donations because of deferrals,
the other reason for the shrinking blood supply is the
decreasing willingness of young people to donate blood.
Fewer than 5% of the presumably eligible donors actu-
ally donate blood, so the untapped population of suita-
ble blood donors is huge [8]. Thus, instead of relaxing
donor eligibility criteria, more imaginative new donor
recruitment, better public awareness and better politi-
cal/societal support of blood donation could solve our
problem without jeopardizing, or appearing to jeopar-
dize (as in the case of re-admission of non-practicing
MSM), the standard of blood safety the public expects.
How safe is our blood?
A basic principle of medical treatment is the Hippo-
cratic oath “primum nihil nocere” ( L a t i n :F i r s t ,d on o
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harms and benefits must be weighed against one
another. As a biological substance from a particularly
poorly controlled source, blood has always been an
obvious way in which pathogens can easily be trans-
mitted. However, screening methods have become avail-
able and have steadily improved blood safety. First,
serological assays became available, which assessed the
immunological response of the host to an infectious
agent, and were later supplemented with NAT tests for
the infectious agent itself. Much of the effort to develop
more sensitive infectious disease marker (IDM) screen-
ing methods was fuelled by the AIDS scandal in the 80s
and 90s, when many patients were infected and killed
by HIV transmitted through contaminated blood pro-
ducts [10-15]. Germany was among the first to imple-
ment NAT for all blood donations for hepatitis B,
hepatitis C and HIV-1 [16,17]. Similar technology is
now in use in one-third of all countries around the
world [18]. A total of 300 million blood donations later,
244, 680 and 1,884 NAT-only positive blood donations
with HIV-1, HCV and HBV, respectively, have been
identified; each likely stands for an averted infection
[18]. NAT technology has shrunk the diagnostic window
between infection and detection to a minimum (< 10
days for HiV and HCV, 30 days for HBV). The residual
risk for HCV, HIV-1 and HBV in Germany was recently
estimated as 1 per 10.88, 4.3 and 0.36 million transfu-
sions, respectively [19]. The power of NAT is particu-
larly apparent in places like South Africa with its high
prevalence of blood-borne infections, where introduc-
tion of NAT managed to control the risk of transfusion-
transmitted virus infection that had been expected to
rise dramatically after inclusion of donors from high-
risk populations [20]. Nevertheless, NAT is more sensi-
tive to subtle changes of the viruses than serology;
mutations within primer and probe binding regions led
to three false-negative NAT results in Germany in 2010
alone [21]. As a consequence, the federal authority
(Paul-Ehrlich-Institute) recently recommended dual-tar-
geting, that is, amplification in two conserved genome
regions, for HIV-1 [21]. An alternative or complemen-
tary strategy to improve blood safety might be imple-
mentation of fourth generation antigen-antibody assays,
which are available for HIV-1 with others to follow suit.
The diagnostic window period will likely be similar to
that of NAT. Emerging pathogens like dengue, Chikun-
gunya and hepatitis E virus or malaria will present
future challenges for blood transfusion services.
As an alternative to ever more sensitive test methods
and ever broader pathogen spectra, global pathogen
inactivation could be implemented. However, the need
for different technologies for the different blood compo-
nents, price, concerns about cell quality, long-term
recipient safety, loss of product and other disadvantages
have thus far impeded wide-spread use of available and
emerging pathogen inactivation technologies.
Because of the sensitive screening methods used
today, blood has become a relatively safe drug. Never-
theless, it should be self-intuitive that any relaxation of
donor deferral rules which allow populations with an
increased risk for certain transmissible diseases to
donate blood, will be associated with an increased risk
for recipients. It is always possible, as we have seen, to
miss infectious agents [21], and a certain window per-
iod, although short, remains. Since relaxation of deferral
criteria has not often been employed, (the South African
example given above [20] being a unique exception),
and numbers for at-risk individuals wishing to become
blood donors are unknown, useful estimates of the risk
increase can not be provided.
Conclusions
Does a society have the right to expect a maximally safe
blood supply if that society is not willing to reciprocate
by donating in adequate quantity? A host of data sug-
gests that in the very near future with our current stra-
tegies we may not be able to satisfy the need for blood,
in significant part because we are failing to recruit new
blood donors from the vast majority of people who
choose not to donate blood even though they would be
eligible by current standards. The alternative to new
donor recruitment would be to relax current eligibility
criteria, which may impact upon safety by allowing
some permanently deferred populations to donate blood
at the potential risk of jeopardizing the safety of blood.
To a degree, that is what the recent decision in the UK
to allow non-practicing MSM to donate blood is doing.
However, we predict that this specific decision will not
have (tangible) adverse effects on blood safety, although
there may be some changes in perceived safety. That
rule change should be seen as a political move, a half-
hearted political nod to MSM, probably partly in
response to student unions’ threats to boycott blood
donor drives in universities unless “discrimination” of
MSM by blood services is discontinued. On its own, the
change will likely only be consequential for blood supply
or blood safety in that it avoids the threatened student
boycott and prevents the loss of those coveted donors.
At the same time, though, it may adversely affect the
public’s perception of blood safety. Only if we can moti-
vate new volunteers to become donors can we avert the
impending public loss of faith in blood products, and
meet the ever-increasing need for these products.
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